Novo Nordisk (NVO) received a warning from the US Food and Drug Administration over the use of false and misleading claims in an ad for the company's Ozempic product, news outlets reported Tuesday.

According to the reports, the ad suggested that all patients with type 2 diabetes Ozempic are eligible for Ozempic's approved indications, but the approved use is for patients who have other conditions apart from diabetes.

The company was given 15 days to respond to the warning, the news outlets said.

Separately, the FDA warned 30 telehealth companies over false or misleading claims over compounded GLP-1 products published on their respective websites, implying that their products are the same with FDA-approved products.